Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Moderator:
Dr. Steve Uden, Head of Research, Alexion Pharmaceuticals

• Opportunities for collaborations with india

Panelists:

• Dr. Ariz Ahammed IAS, Joint Secretary, Department of Pharmaceuticals, Govt. of India

1. Silos in the indian Government are high and a need to communicate and collaborate is much needed
2. collaborations 4 took place past year
3. Institutional Collaboration requires investment in Scientists
4. Academics focus on publications, in Pharmaceuticals – deliverables are different that publications

• Dr. Barry Bloom, Distinguished Service Professor, Harvard School of Public Health

1. Interest is high in the US f fro Partnerships with global players
2. India 1.2% of GDP is spent on Health in the US 17.4%
3. In India Great Research Centers NOT connected to Hospitals or Industry
4. Partnerships need be developed first in side India
5. Public Health in India: Public Sector vs Private Sector for Infectious diseases
6. Would like to see Global needs that India has advantages, monopoly on infection diseases in India, investment in anti-microbial declined in the US to minimum, India can make great contributions in anti-microbial
7. What are the incentives to pursue collaborations?
8. The government must play a role in India like NIH, NSF, CDC in the US

• Dr. Peter Mueller, President of R&D and Chief Scientific Officer, Pronutria BioSciences

1. Problems in need to be solved are different not all can be in-house, reaching out to people and seeking technologing and relationships
2. Networks not Silos as in the 80s, in 2016 behaviors and business model and sharing of information – advantages for new uses to same patents
3. In the manhattan Projects a lot was accomplished across institutions and understand the interdependencies vs optimizing own’s environment
4. people management with well defined interactions and relationships and roles
5. convergence of Science Innovations, India has the potential to become at the top of the Scientific Community, there are Centers that demonstrates outstanding success

• Dr. Andrew Plump, Chief Medical & Scientific Officer, Takeda Pharmaceuticals

1. Value of Partnerships as fundamental to business is today more the case then in the near Past
2. Partnership increase is a function of Internal R&D Costs that are too high
3. What models work? Relationship with a Partner – Mindset of being agile, both parties need to win, synergi=y needs be accomplished, small company to commercialize – Partnerships vs Exit is the strategy at Present
4. Investments in NYC, Munich, Singapose, in the US: SF, Boston, SanDiego, UK: Cambridge
5. Hospitals in India for 2.1 Billion

• Anil Raghavan, Chief Executive Officer, Sun Pharma Advanced Research Company

1. Ideas can come from all over the world, US: Boston, San Francisco where the competition is high
2. the tradisional structure of institutions need to change to allow for collaborations – protection of each institution

Questions from the Floor:

• Patients participate in Clinical Studies

Moderator:
Dr. William Chin, Executive Vice President, PhRMA

• What diagnostics can be developed for the HealthCare Market in India
• Translational Research and basic research — WHich is more importnat – Dr. CHin: Translational

Dr Griffin Rodgers, Director, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health

• One of 27 Institutes of the NIH
• 85% of budget supports Scientists OUTSIDE the NIH
• Collaborative research over $1Billion NIH invested in Diabetes
• National Diabetes Federation highlights that in the US, India, China – will have same number of patients affected by Diabetes
• 2012  Joint agreement for collaboration
• Research Trends in Diabetes: Resistence in DM2
• Partnership: Academia, Medical Partnerships to discovery new therapeutics for DM2, other initiatives: Autoimmune, CVD – Data sharing: Academics and Industry, NIH research and Hospitals 
• to 2019 – when all data will be all accessible by American Diabetes Association
• Receptors and co-activations, Kinases, ion-channels
• Agreement in 2013 to develop: DM-HIV-TB collaboration with india.
• DM@ Patients have an increase infectivity for HIV and TB !!
• Glacemia monitoring statins controlling lipids, cost effective treatment
• Kidney disease is a complecation of Diabetes: DM1 it is possible to control kidney disease by drugs

Moderator:
Colin Hill, Chairman & CEO, GNS Healthcare

1. Chemo therapy still is the backbone – this is changing
2. success of monoclonal antibodies
3. Target therapy
4. Patient selection strategy — will speed drug development and cost effectiveness will increase
5. cost containment by Payers
6. uptake of Biomarker research to perfect them
7. embed Biomarket with the drug, or with the therapy lab work

• top 3 transformations in ImmunoOncology, CRISPR, Value-Outcome

Panelists:

• Dr. Bruce Chabner, Director of Clinical Research, MGH Cancer Center

1. FDA – Biomarkers need be developed
2. Understanding Drug resistance

• Dr. Arun Chandavarkar, CEO & Joint Managing Director, Biocon

1. Value
2. Drug affordability

• Dr. Gordon Freeman, Professor of Medicine, Dana-Farber Cancer Institute/HMC

1. PDL1 – expresses in vivo on tumor surface
2. tumon turn off immune response
3. combination with the Foundation therapy PDL-1
4. reeducation of oncologist on adverse effects that are differennt from these of CHemo
5. Multiple PDL1 actors, BioSimilars small molecules will emerge to mimic the effect
6. PDL1 – can be a commodiyt for many more Patients
7. 10% adverse effects of immune systems for PDL1
8. 70% correlation of Biomarker and drugs – not like precision gene testing
9. clonal viral: Viral diseases – low cost PD! possibility for underdeveloed countries

• Dr. Sandeep Gupta, President & CEO, Asana BioSciences

1. Combination
2. time to success is too long

• Dr. Rakesh Jain, Director, E.L. Steele Laboratory of Tumor Biology, MGH Cancer Center

1. checkpoint are effective

• Dr. Daniel Omstead, President & CEO, Tekla Capital Management

1. Combination drug therapy – how the reimbursements
2. Regulatory and reimbursement – adaptive clinical trial design, diagnostics
3. Novel vs small follow ups